Glorimet G 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. The combination provides complementary mechanisms of action, offering effective glycemic regulation in patients inadequately controlled by diet, exercise, or monotherapy. Glorimet G 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to assess therapeutic response and adjust dosage accordingly. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to Metformin, while Glimepiride may cause hypoglycemia, especially if meals are skipped or in cases of overdose. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Regular monitoring of renal function and blood glucose is essential to ensure safety and efficacy during treatment with Glorimet G 2 Tablet PR.